natural glp 1 receptor agonist Crystal structure of the GLP-1 bound to a peptide GLP-1s, Gut Motility & IBS

If additional A1C lowering is needed, may increase to 1.5 mg once weekly, 3 mg (after 4 weeks on 1.5 mg dose), then 4.5 mg (after 4 weeks on 3 mg dose)

Synthetic GLP-1 drugs can be effective but may carry long-term risks

A meta-analysis [74] including the ELIXA [66], LEADER [44], SUSTAIN-6 [67], EXSCEL [68], REWIND [70], and AMPLITUDE-O [51] studies found that GLP-1RAs were associated with better renal outcomes: a 30% or 40% or more decrease in glomerular filtration rate, need for renal replacement therapy, end-stage renal failure, or death from kidney disease by 21%

3,4 GLP-1RAs mimic the action of endogenous GLP-1, activating GLP-1R, thereby enhancing insulin secretion, inhibiting glucagon release, delaying gastric emptying, and reducing food intake through central appetite suppression

the victim drug is the drug affected by the DDI

Calibrators were prepared by spiking blank NHP-plasma with NNC0487-0111 in the range from 0.5200 nM